#USA #multi-omics #Helix #Precure #Rochester, Minnesota

Precure and Helix: Pioneering the Future of Precision Medicine

In a groundbreaking collaboration, Precure, LLC has chosen Helix as its provider for multi-omic laboratory services and artificial intelligence tools. This partnership aims to bolster efforts to generate extensive molecular data from a staggering one million biospecimens, facilitating a significant leap forward in the realm of precision medicine.

The announcement, made on September 21, 2026, comes days after the launch of Precure, LLC, a joint initiative established by the Mayo Clinic and Thermo Fisher Scientific. This collaboration looks to revolutionize how the life sciences sector comprehends the biological transformations that occur during disease progression, often before any noticeable symptoms appear.

Bridging Genomics and Clinical Practice

Helix’s commitment includes the provision of cutting-edge AI tools designed to integrate genomics seamlessly into clinical settings, thereby enhancing biomarker-driven research. The company's capabilities will extend to population-scale multi-omic technologies, incorporating clinical whole genome sequencing (WGS) and proteome sequencing. By marrying these advanced methods with longitudinal clinical data and high-performance computing infrastructure, this initiative seeks to uncover new avenues for the prevention, diagnosis, and treatment of ailments.

Dr. Aaron Mangold, Chief Medical Officer at Precure, emphasized the mission of this program: “Our goal is to generate genomic information that can help inform patient care while creating a powerful resource for discovery.” He identifies the foundation of care as being clinical whole genome sequencing and multi-omic approaches, which aim to detect diseases earlier than ever before.

To ensure the success of this monumental initiative, Precure, LLC plans to utilize Helix's innovative Exome+® sequencing technology in conjunction with the Ultima Genomics' UG200™ Ultra Sequencing Platform. This state-of-the-art system is integral to achieving high-quality genomic data generation necessary for both WGS and proteomics on a grand scale.

Transforming the Healthcare Landscape

According to Dr. James Lu, CEO of Helix, “The genome is becoming an enduring patient resource, providing a precision baseline for a lifetime of care.” This statement underscores the significance of genomic data in establishing a comprehensive foundation for ongoing patient management.

The involvement of the Mayo Clinic in Precure is not just a business endeavor; it aligns with their long-standing nonprofit mission. Any financial returns generated will be reinvested into patient care, research, and educational initiatives. This commitment to altruism ensures that advancements in healthcare will directly benefit the community, propelling innovations in diagnostics, therapeutics, and overall healthcare solutions.

The Bigger Picture

Precure, LLC is not merely a business venture but a critical entity working towards generating and responsibly integrating large-scale molecular data with consistent clinical information. By facilitating external collaborations and enabling disease-focused discoveries, the company plans to accelerate the development of groundbreaking healthcare solutions. Such endeavors are poised to complement Mayo Clinic's investigator-led research and clinical activities, raising the standard of care across the healthcare spectrum.

This partnership between Precure and Helix stands as a hopeful beacon for the future of healthcare, aiming to arm physicians with vital genomic insights that drive patient-centered care and treatment methodologies. For more detailed information on this collaboration, visit Mayo Clinic’s Precure page.